S. Otto

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy

D. Niederwieser, H. Al-Ali, R. Krahl, 2004 .

Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation

M. Deininger, D. Niederwieser, H. Al-Ali, 2005, Leukemia.

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

S. McWeeney, B. Druker, M. Deininger, 2005, Blood.

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible

G. Behre, M. Cross, U. Platzbecker, 2020, Frontiers in Oncology.

Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment.

S. McWeeney, B. Druker, M. Deininger, 2004 .

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

S. McWeeney, B. Druker, M. Deininger, 2005, Blood.

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

D. Niederwieser, H. Al-Ali, R. Krahl, 2004, Haematologica.